Noveris Health Sciences Inc. News Releases

Noveris Health Sciences Announces Results of 2026 Annual General and Special Meeting

Wed, 09 Sep 2026 17:05:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") announces the results of its annual general and special meeting of shareholders held on September 4, 2026 (the "Meeting").A total of 21,697,593 common shares of the Company were represented at the Meeting, representing approximately 37.06% of the 58,548,051 common shares issued and outstanding and entitled to vote at the...

Noveris Health Sciences Announces Proposed Private Placement of Convertible Debentures for up to $500,000

Thu, 20 Aug 2026 18:14:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - August 20, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") is pleased to announce its intention to complete a non-brokered private placement of convertible debentures of the Company (the "Debentures") in an aggregate principal amount of up to $500,000, issuable in increments of $1,000 principal amount, for aggregate gross proceeds of up to $500,000 (the "Offering"). The Offering is expected...

Noveris Health Sciences Receives USPTO Notice of Allowance, and Signs Work Order with API

Tue, 18 Aug 2026 17:05:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - August 18, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) ("Noveris" or the "Company") is pleased to announce that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for the Company's U.S. Patent Application No. 18/443,025, titled "Aza-Substituted Psilocin Analogs and Methods of Synthesizing the Same."The Notice of Allowance confirms that all six claims in the application have...

Noveris Health Sciences Inc. Unaware of Any Material Change

Thu, 06 Aug 2026 14:05:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - August 6, 2026) - At the request of CIRO, Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity.Noveris is a Canadian life sciences company focused on opportunities in mental health and therapeutic innovation. Additional information...

Noveris Health Sciences Joins BioAlberta

Thu, 30 Jul 2026 17:05:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - July 30, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") announces that it has become a member of BioAlberta, a not-for-profit industry association representing Alberta's life sciences community.BioAlberta supports its members through industry development, educational and networking activities, and engagement on matters affecting Alberta's life sciences sector. Its membership includes...